Heuron Selected for Government-Supported Project to Digitally Transform AI-Based Medical Systems

Jun. 2025

Heuron Inc. (CEO Donghoon Shin), a company specializing in AI solutions for neurological disorders, has been selected for the “AI-Based Medical System Digital Transformation Support Project” led by the National IT Industry Promotion Agency (NIPA).


This project aims to evaluate the multi-center clinical validation and practical effectiveness of AI-assisted stroke diagnostic solutions in public healthcare settings. It will run for approximately 19 months, from May 2025 to December 31, 2026.


As the lead organization, Heuron will collaborate with participating institutions including Chonnam National University Hospital, Kyungpook National University Hospital, and Chungnam National University Hospital. The project is backed by KRW 1.74 billion (approximately USD 1.3 million) in government funding.


Heuron will undertake key initiatives such as:

- Deploying its AI solutions in regional public hospitals

- Reducing the time from admission to treatment for emergency stroke patients

- Verifying improvements in patient outcomes

- Evaluating the usability of the AI in clinical practice


Through this project, Heuron aims to establish the credibility of domestic medical devices and generate evidence to support their expansion across public healthcare institutions.


Following the project, Heuron plans to leverage the outcomes and clinical evidence to pursue health insurance reimbursement for its stroke AI suite—Heuron StroCare Suite™—and to expand its adoption in certified stroke centers across Korea. The company will also focus on building global clinical evidence and assessing international market potential to support overseas expansion.


CEO Donghoon Shin commented, “This initiative represents an excellent opportunity for our stroke AI solutions to enhance the quality of care in regional public hospitals and to contribute to a more efficient, locally-centered healthcare ecosystem. We are fully committed to generating robust clinical evidence so that our product can become a truly valuable tool in real-world settings and ultimately gain recognition in global markets.”

TOP